Terns Pharmaceuticals, Inc. (TERN) Form 8-K — May 5, 2026
$TERNForm 8-KItems 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01Filed May 5, 2026, 9:21 AM ET0001193125-26-205305Original filing
Merck Sharp & Dohme LLC has completed its acquisition of Terns Pharmaceuticals, Inc. for $53.00 per share in cash. The tender offer expired on May 4, 2026, with approximately 86.36% of outstanding shares validly tendered and not withdrawn. Following the expiration of the offer, Purchaser accepted the tendered shares, and the merger became effective on May 5, 2026.
Key figures
- Offering Price
- 53.00
- Shares Outstanding
- 100,091,794
- Shares Tendered
- 100,091,794
- Percent Tendered
- 86.36%
Price after filing
1 day: 0.0%7 days: 0.0%
Close on the filing date to close N calendar days later (from $52.95). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.